Holly Kordasiewicz Sells 4,141 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Holly Kordasiewicz sold 4,141 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $75.66, for a total transaction of $313,308.06. Following the sale, the executive vice president owned 14,718 shares of the company’s stock, valued at approximately $1,113,563.88. The trade was a 21.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Ionis Pharmaceuticals Trading Up 1.6%

Shares of Ionis Pharmaceuticals stock traded up $1.20 during mid-day trading on Tuesday, hitting $77.53. The stock had a trading volume of 4,894,343 shares, compared to its average volume of 1,492,706. The firm has a 50-day moving average of $78.90 and a two-hundred day moving average of $64.33. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $86.15. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The firm has a market cap of $12.56 billion, a P/E ratio of -45.88 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.35. The firm had revenue of $156.72 million for the quarter, compared to analysts’ expectations of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 44.26% and a negative net margin of 26.45%.The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.95) earnings per share. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IONS. Golden State Wealth Management LLC increased its position in shares of Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth $25,000. Mather Group LLC. acquired a new position in shares of Ionis Pharmaceuticals during the third quarter worth $27,000. Quarry LP purchased a new position in Ionis Pharmaceuticals in the third quarter valued at $38,000. Finally, Johnson Financial Group Inc. purchased a new position in Ionis Pharmaceuticals in the third quarter valued at $44,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Wall Street Analyst Weigh In

Several brokerages have weighed in on IONS. Leerink Partners increased their target price on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Raymond James Financial reiterated a “strong-buy” rating and issued a $89.00 target price (up previously from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. TD Cowen upped their price target on Ionis Pharmaceuticals from $59.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Piper Sandler lifted their price objective on Ionis Pharmaceuticals from $70.00 to $77.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, Royal Bank Of Canada increased their target price on Ionis Pharmaceuticals from $82.00 to $95.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.05.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.